How would KBI Biopharma highlight its achievements in 2025? Which key projects strengthened the company’s global C...
Significant strides have been made in the detection and treatment of cancer in the last two decades. However, while surv...
Asia-Pacific’s life sciences landscape has always been shaped by contrasts. It is a region where scale and sophist...
The Japanese government has stepped up efforts to strengthen its startup ecosystem, rolling out a series of initiatives ...
The World Health Organization (WHO) estimates that more than 2.2 billion people worldwide live with some form of vision ...
The COVID-19 pandemic acted as both a challenge and a catalyst, serving as a testbed that fundamentally reshaped the bio...
mRNA first entered the global spotlight during COVID-19, turning companies such as Moderna and BioNTech into household n...
Register Now Asia Pacific’s biomanufacturing landscape is entering a defining decade, and the ina...
China has reached a major milestone in global pharmaceutical innovation. According to the latest report from Clarivate, ...
According to reports, the APAC MedTech market is valued at $16.3 billion in 2025, with a potential to reach $18.6 billio...
Beyond tariff cuts, FTAs deliver deep structural benefits through regulatory alignment and facilitation of trade. Firms ...
In both the US and Japan, regulators provide an extensive set of resources detailing the rules and specifications govern...
For much of the past century, Alzheimer’s disease has been one of medicine’s most daunting frontiers—b...
The Asia-Pacific biotech sector is entering 2026 with renewed momentum. Investment in the pre-clinical organoid space co...
In today’s global, multi-provider clinical trial environment, sponsors need to rapidly and accurately assess vast ...
In 2026, oncology drug development in Asia may move away from the historical maximum tolerated dose (MTD) paradigm towar...
2025 was the year when China’s stratospheric rise on the global biotech stage continued. According to a report fro...
When Najat Khan steps into her new role as CEO and President of Recursion, she inherits more than a celebrated...
